<DOC>
	<DOCNO>NCT00261352</DOCNO>
	<brief_summary>This 24-week study determine lipid metabolic effect , safety , tolerability tesaglitazar compare metformin metformin combination fenofibrate patient type 2 diabetes low high-density lipoprotein cholesterol ( HDL-C ) . Improvement dyslipidemia evaluate . The study comprise 2-week enrollment period , 6-week run-in 24-week randomize , double blind , parallel group , multi-center , active control ( metformin without fenofibrate ) treatment period 3-week follow-up . From visit 2 ( run-in ) , patient receive standardize dose statin ( rosuvastatin )</brief_summary>
	<brief_title>GALLANT 14 Tesaglitazar vs. Metformin Fenofibrate</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Provision write informed consent Men woman &gt; =18 year age Female patient : postmenopausal , hysterectomized , childbearing potential , use reliable method birth control Diagnosed type 2 diabetes Treated diet alone treatment single oral antidiabetic agent low dos two oral antidiabetic agent Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level normal range Received investigational product clinical study within 12 week Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>